Evidence map›Paper›PMID 41175344›Full record

ArticleRNA biology2025

RNA binding of GAPDH controls transcript stability and protein translation in acute myeloid leukemia.

Sama Shamloo, Jeffrey L Schloßhauer, Shashank Tiwari, Kim Denise Fischer, Omar Almolla, Yohana Ghebrechristos, Lisa Kratzenberg, Aathma Merin Bejoy, Ioannis Aifantis, Francesco Boccalatte and 2 more

Abstract read
In one paragraph

Article in RNA biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Cysteine-S-nitrosylation inhibits Rop5-mediated immune evasion inbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sama ShamlooChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Jeffrey L SchloßhauerChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Shashank TiwariChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Kim Denise FischerChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Omar AlmollaCandiolo Cancer Institute, FPO-IRCCS, Candiolo(To), Italy.
Yohana GhebrechristosDepartment of Pathology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Lisa KratzenbergChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Aathma Merin BejoyChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.
Ioannis AifantisDepartment of Pathology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Francesco BoccalatteCandiolo Cancer Institute, FPO-IRCCS, Candiolo(To), Italy.
Eric WangThe Jackson Laboratory for Genomic Medicine, Farmington, USA.
Jochen ImigChemical Genomics Centre of the Max Planck Society, Dortmund, Germany.ORCID 0000-0003-0385-1081

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Paul Robson · 1985 to 2026
$61.9M
Dissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2M
Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7M
Regulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
NCI NIH HHS P30 CA034196NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA271455NHLBI NIH HHS R01 HL159175
6 · The paper itself

Abstract

Dysregulation of RNA binding proteins (RBPs) is a hallmark in cancerous cells. In acute myeloid leukaemia (AML) RBPs are key regulators of tumour proliferation. While classical RBPs have defined RNA binding domains, RNA recognition and function in AML by non-canonical RBPs (ncRBPs) remain unclear. Given the inherent complexity of targeting AML broadly, our goal was to uncover potential ncRBP candidates critical for AML survival using a CRISPR/Cas-based screening. We identified the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a pro-proliferative factor in AML cells. Based on cross-linking and immunoprecipitation (CLIP), we are defining the global targetome, detecting novel RNA targets mainly located within 5'UTRs, including GAPDH, RPL13a, and PKM. The knockdown of GAPDH unveiled genetic pathways related to ribosome biogenesis, translation initiation, and regulation. Moreover, we demonstrated a stabilizing effect through GAPDH binding to target transcripts including its own mRNA. The present findings provide new insights on the RNA functions and characteristics of GAPDH in AML.

Indexed as

Glyceraldehyde-3-Phosphate DehydrogenasesLeukemia, Myeloid, AcuteProtein BiosynthesisRNA, MessengerRNA Stability5' Untranslated RegionsCell Line, TumorCell ProliferationGene Expression Regulation, LeukemicGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)HumansProtein BindingRNA-Binding Proteins5' Untranslated RegionsGAPDH protein, humanGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)Glyceraldehyde-3-Phosphate DehydrogenasesRNA-Binding ProteinsRNA, MessengerAMLGlyceraldehyde-3-phosphate dehydrogenasemRNA stabilizationribosome-nascent chain complexRNA binding proteintranslation

Identifiers

PMID41175344
PMCPMC12582121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.